Stoke Therapeutics (NASDAQ:STOK) had its price target raised by investment analysts at Needham & Company LLC from $56.00 to $65.00 in a research report issued on Thursday, AnalystRatings.net reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price objective points to a potential upside of 11.68% from the company’s current price.
STOK has been the topic of a number of other research reports. Canaccord Genuity boosted their price objective on shares of Stoke Therapeutics from $53.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, December 28th. JPMorgan Chase & Co. initiated coverage on Stoke Therapeutics in a research report on Tuesday, September 29th. They set a “neutral” rating for the company. BTIG Research raised their price objective on Stoke Therapeutics from $46.00 to $68.00 and gave the stock a “buy” rating in a report on Friday, November 13th. Cantor Fitzgerald assumed coverage on Stoke Therapeutics in a research note on Friday, October 23rd. They issued an “overweight” rating and a $49.00 price objective on the stock. Finally, Credit Suisse Group boosted their target price on Stoke Therapeutics from $42.00 to $49.00 and gave the stock an “outperform” rating in a report on Friday, November 13th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Stoke Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $56.86.
Shares of STOK opened at $58.20 on Thursday. The stock has a 50 day moving average price of $55.86 and a 200 day moving average price of $38.47. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -32.33 and a beta of 0.23. Stoke Therapeutics has a 52-week low of $15.82 and a 52-week high of $64.54.
In related news, COO Huw M. Nash sold 5,700 shares of Stoke Therapeutics stock in a transaction dated Monday, January 4th. The stock was sold at an average price of $58.97, for a total transaction of $336,129.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gene Liau sold 5,851 shares of the business’s stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $40.00, for a total value of $234,040.00. Following the transaction, the executive vice president now owns 19,351 shares in the company, valued at $774,040. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 331,348 shares of company stock valued at $15,311,424. Corporate insiders own 54.60% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. California Public Employees Retirement System raised its stake in Stoke Therapeutics by 70.7% during the second quarter. California Public Employees Retirement System now owns 24,700 shares of the company’s stock worth $589,000 after acquiring an additional 10,230 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Stoke Therapeutics by 583.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 143,184 shares of the company’s stock worth $3,412,000 after buying an additional 122,228 shares during the period. FMR LLC raised its holdings in Stoke Therapeutics by 65.5% during the 2nd quarter. FMR LLC now owns 771,866 shares of the company’s stock worth $18,394,000 after buying an additional 305,519 shares during the period. Vanguard Group Inc. raised its holdings in shares of Stoke Therapeutics by 60.6% during the second quarter. Vanguard Group Inc. now owns 1,278,341 shares of the company’s stock worth $30,462,000 after acquiring an additional 482,351 shares during the period. Finally, Bank of America Corp DE raised its stake in shares of Stoke Therapeutics by 56.5% in the 2nd quarter. Bank of America Corp DE now owns 9,156 shares of the company’s stock valued at $218,000 after purchasing an additional 3,307 shares during the period.
About Stoke Therapeutics
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer genetic testing.
See Also: What is the Nikkei 225 index?
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.